99精品视频在线观看免费-国产成人久久精品一区二区三区-国产亚av手机在线观看-久久精品亚洲中文字幕无码网站-欧美肥婆姓交大片-日韩毛片无码永久免费看

Wuxi Gotele Metal Products Co., Ltd : CN EN
首頁 >>新聞動態 >>醫療設備新聞

Chinese Cell Therapy Effective in Small Multiple Myelome Trial

Recently, China’s Nanjing Legend Biotech Co. conducted a trial testing the effectiveness of an experimental therapy to treat multiple myeloma. Multiple myeloma is a rate form of blood plasma cancer. The trial proved successful, meaning it induced remission in most patients including those with advanced multiple myelmoa. The trial uses a new drug that utilizes CAR-T therapies, a relatively new medical innovation. 


How It Works

The study run and developed by Nanjing Legend Biotech Co. tested a chimeric antigen receptor T-cell (CAR-T) therapy thirty-five patients. Of the thirty-five nineteen were used in the trial.  Of the nine-teen patients, fourteen reached complete remission after fourth months. The American Society of Clinical Oncology featured the data at their annual meeting. The drug candidate used is known as LCAR-B38M. It is designed to target a protien called BCMA, which is found on cancerous blood plasma cells. CAR-T therapies require a difficult process. It first requires the extraction of immune system T cells from the patient, then their DNA is altered to sharpen their ability to spot and kill cancer cells, lastly the altered cells are infused back into the same patient. Using this technology not only treats the cancer, it offers the possibility for long term remission.  However, there were some negative side effects that came with many patients in the trial. Nearly 85% of patients temporarily developed cytokine release syndrome (CRS). CRS is a potoentially life-threatening inflammatory condition, but the condition was only temporary and easily managed using anti-inflammatory medications.

Continued Use

Due to the positive response experienced by so many in the small trial, China’s Nanjing Legend Biotech Co. hopes to enroll 100 new patients into the trial . They also desire to find other collaborators in the US to conduct a smilar trial in the United States starting as early as 2018.  As of now, two US companies have filed for FDA approval to use CAR-T drugs designed to target different protiens. The FDA will make its decision to approve or dissapprove of these therapies by November 29,2017. If approved CAR-T therapies can be used to treat and induce remission in advanced non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. These advances in medical innovations are putting us one step closer to curing hundreds of diseases and illnesses plaguing millions of people around the world.


首頁電話產品導航
CN EN
主站蜘蛛池模板: 亚洲欧美国产精品无码中文字| 国产热re99久久6国产精品首页| 青青草原综合久久大伊人精品| 中国免费看的片| 精品亚洲国产成人av制服| 日韩视频 中文字幕 视频一区| 伦理精品在线| 欧美亚洲日本国产综合在线| www国产无套内射com| 国产强奷伦奷片| 国内精品一区二区三区| 久久99精品这里精品6| 亚洲综合一区二区三区四区五区| 饥渴丰满少妇大力进入| 无码h黄动漫在线播放网站| 久久久久久成人毛片免费看| 亚洲国产成人高清在线观看| 天天爽天天爽天天爽| 99热这里只就有精品22| 乱码人妻一区二区三区| 91精选国产大片| 无码h黄肉3d动漫在线观看| 久久99国产精品尤物| 久久亚洲精品成人无码网站夜色 | 国产精品久久久久这里只有精品| 无码日韩精品一区二区免费暖暖| 国产成人av无码片在线观看| 少妇被黑人到高潮喷出白浆| 囯产精品一品二区三区| 国产又黄又湿无遮挡免费视频| 开心五月激情综合婷婷色| 久久男人av资源网站| 亚洲成a∨人片在线观看无码| 国产精品日本一| 成人亚洲性情网站www在线观看| 99久久久成人国产精品免费| 中文字幕巨大的乳专区| 特黄特色大片免费播放| 欧美真人性野外做爰| 国产又黄又爽又色的免费视频| 99国内精品久久久久影院|